In an amicus brief, the American Medical Association warns of interference with medical judgments.
The final recommendation on screening for prostate cancer issued May 8 by the U.S. Preventive Services Task Force, which gives a “C” grade for PSA testing in men 55-70 years of age, has been met with mixed reviews by prostate cancer-focused organizations, some of which continue to call for legislation to reform the task force itself.
Bob Gatty recaps the recent Annual Urology Advocacy Summit in Washington.
Urologists can claim substantial victories as a result of the Bipartisan Budget Act of 2018, signed into law by President Trump in February—including an end to the Independent Payment Advisory Board, which had been established by the Affordable Care Act to help control Medicare spending.
If the Medicare Payment Advisory Commission has its way with Congress, urologists and other Medicare providers will be subjected to a new payment system, replacing the Merit-based Incentive Payment System that was established when the sustainable growth rate formula was ditched in 2015.
Several medical societies, including the AUA and the American Society of Clinical Oncology, are urging congressional leaders to prevent CMS from applying MIPS adjustments to Part B drug payments.
Legislation that advocates believe would significantly reduce prostate cancer misdiagnoses is making its way through Congress and has the support of major urologic organizations and prostate cancer interest groups.
Nearly three-fourths of men with very low-risk prostate cancer underwent active surveillance as a primary therapy, according to a study presented at the LUGPA annual meeting in Chicago.
The association and its member groups are “leading the way” in developing urology-specific measures that can be used for MIPS quality reporting, says LUGPA President Neal D. Shore, MD.
In his health policy briefing, Deepak A. Kapoor, MD, discusses LUGPA’s comments to CMS regarding MACRA and the 2018 Medicare physician fee schedule.